Literature DB >> 24862316

Nanotherapy for posterior eye diseases.

Indu Pal Kaur1, Shilpa Kakkar2.   

Abstract

It is assumed that more than 50% of the most enfeebling ocular diseases have their origin in the posterior segment. Furthermore, most of these diseases lead to partial or complete blindness, if left untreated. After cancer, blindness is the second most dreaded disease world over. However, treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted for delivery to this segment. In this regard, nanostructured drug delivery systems are proposed to defy ocular barriers, target retina, and act as permeation enhancers in addition to providing a controlled release. Since an important step towards developing effective treatment strategies is to understand the course or a route a drug molecule needs to follow to reach the target site, the first part of the present review discusses various pathways available for effective delivery to and clearance from the posterior eye. Promise held by nanocarrier systems, viz. liposomes, nanoparticles, and nanoemulsion, for effective delivery and selective targeting is also discussed with illustrative examples, tables, and flowcharts. However, the applicability of these nanocarrier systems as self-administration ocular drops is still an unrealized dream which is in itself a huge technological challenge.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bevacizumab; Controlled release; Delivery to the vitreous; Fluorescein isothiocyanate-dextran; Ganciclovir (PubChem CID: 3454); Liposomes; Methoxypoly(ethylene glycol)-poly(β-caprolactone); Nanoparticles; Poly(ethylene glycol); Poly(lactide-co-glycolide); Polyethyleneimine; Ranibizumab; Retina; Rostaporfin (PubChem CID: 23725012); Topical delivery; Verteporfin (PubChem CID: 5362420)

Mesh:

Substances:

Year:  2014        PMID: 24862316     DOI: 10.1016/j.jconrel.2014.05.031

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  26 in total

1.  Synthesis and Characterization of Ganciclovir Long Chain Lipid Prodrugs.

Authors:  Kishore Cholkar; Hoang M Trinh; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Adv Ophthalmol Vis Syst       Date:  2014-08-27

2.  Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection.

Authors:  Huiling Li; Mallika Palamoor; Monica M Jablonski
Journal:  Nanotoxicology       Date:  2016-05-16       Impact factor: 5.913

3.  An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration.

Authors:  Lei Zhao; Guojun Chen; Jun Li; Yingmei Fu; Timur A Mavlyutov; Annie Yao; Robert W Nickells; Shaoqin Gong; Lian-Wang Guo
Journal:  J Control Release       Date:  2017-01-04       Impact factor: 9.776

Review 4.  A holistic approach to targeting disease with polymeric nanoparticles.

Authors:  Christopher J Cheng; Gregory T Tietjen; Jennifer K Saucier-Sawyer; W Mark Saltzman
Journal:  Nat Rev Drug Discov       Date:  2015-01-19       Impact factor: 84.694

Review 5.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

Review 6.  Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.

Authors:  Joanne D Du; Wye-Khay Fong; Suzanne Caliph; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

Review 7.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

Review 8.  Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness.

Authors:  Igor Khalin; Renad Alyautdin; Ganna Kocherga; Muhamad Abu Bakar
Journal:  Int J Nanomedicine       Date:  2015-04-30

9.  Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits.

Authors:  Pranjal S Taskar; Akash Patil; Prit Lakhani; Eman Ashour; Waseem Gul; Mahmoud A ElSohly; Brian Murphy; Soumyajit Majumdar
Journal:  Transl Vis Sci Technol       Date:  2019-09-19       Impact factor: 3.283

Review 10.  Dexamethasone intravitreal implant in the treatment of diabetic macular edema.

Authors:  Pravin U Dugel; Francesco Bandello; Anat Loewenstein
Journal:  Clin Ophthalmol       Date:  2015-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.